Proceedings of the National Academy of Sciences · 1986 · 234 citations · 29 references
MedicineCancer BiologyOncologyCancer PharmacologyMolecular OncologyOncogenesCancer ImmunotherapyTherapeutic Antibody DevelopmentTherapeutic Monoclonal AntibodiesTumor AntigensTumor-associated AntigensAntibodiesCell-surface Antigen TargetingGlycoprotein Tumor AntigensMonoclonal Antibodies In CancerMonoclonal Antibodies In OncologyMonoclonal Antibody RecognitionMonoclonal Antibody SpecificityNeuroblastoma Biology
The neu oncogene encodes a 185-kDa transmembrane glycoprotein tumor antigen, termed p185. We have recently described a monoclonal antibody reactive with a cell surface domain of the p185 molecule. In vivo treatment with this anti-p185 monoclonal antibody was able to significantly inhibit the tumorigenic growth of neu-transformed NIH 3T3 cells implanted into nude mice. Such treatment had no effect on the tumorigenic growth of Ha-ras-transformed NIH 3T3 cells. Furthermore, anti-p185 antibody treatment was able to inhibit the growth of the rat neuroblastoma cells from which the neu oncogene was initially isolated. These results demonstrate that a monoclonal antibody reactive with the extracellular domain of an oncogene-encoded protein can exert a significant antitumor effect; such antibodies may prove useful in the therapy of certain malignancies.
29
Continuous cultures of fused cells secreting antibody of predefined specificity
Georges Köhler, César Milstein · Nature · 1975 · 17.2K citations
Pharmacy, Cell Biology, Immunology +11
Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
Frank Cuttitta, Desmond N. Carney, James L. Mulshine et al. · Nature · 1985 · 1.4K citations
Medicine, Cancer Biology, Oncology +11
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
Alan L. Schechter, David F. Stern, Lalitha Vaidyanathan et al. · Nature · 1984 · 1.2K citations